Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sodium sulfate
Accession Number
DB09472  (DB09476)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.

Structure
Thumb
Synonyms
  • Anhydrous sodium sulfate
  • Sodium sulfate anhydrous
  • Sodium sulfate, anhydrous
  • Sodium sulphate anhydrous
  • Sodium sulphate, anhydrous
  • Sulfuric acid disodium salt, anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Sodium sulfate decahydrate0YPR65R21J7727-73-3RSIJVJUOQBWMIM-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Sulfate ionionic7IS9N8KPMG14808-79-8QAOWNCQODCNURD-UHFFFAOYSA-L
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bi-peglyteSodium sulfate (5.74 g) + Bisacodyl (5 mg) + Polyethylene glycol (59.55 g) + Potassium chloride (0.76 g) + Sodium bicarbonate (1.69 g) + Sodium chloride (1.46 g)Kit; Powder, for solution; Tablet, delayed releaseOralPendopharm Division Of Pharmascience Inc2010-06-06Not applicableCanada
Clenz-LyteSodium sulfate (22.74 g/4L) + Polyethylene glycol (236 g/4L) + Potassium chloride (2.97 g/4L) + Sodium bicarbonate (6.74 g/4L) + Sodium chloride (5.86 g/4L)Powder, for solutionNasogastric; OralPaddock Laboratories, Inc.2010-06-072010-06-07Us
ColPrep KitSodium sulfate decahydrate (17.5 g/22.7g) + Magnesium sulfate (1.6 g/22.7g) + Potassium sulfate (3.13 g/22.7g)Powder, for solutionOralKvk Tech,Inc2016-12-27Not applicableUs
ColyteSodium sulfate decahydrate (21.5 g/3.785L) + Polyethylene glycol (227.1 g/3.785L) + Potassium chloride (2.82 g/3.785L) + Sodium bicarbonate (6.36 g/3.785L) + Sodium chloride (5.53 g/3.785L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical2010-09-012016-05-31Us
ColyteSodium sulfate (81.2 mg) + Polyethylene glycol (857.69 mg) + Potassium chloride (10.65 mg) + Sodium bicarbonate (24.02 mg) + Sodium chloride (20.87 mg)Powder, for solutionNasogastric; OralPendopharm Division Of Pharmascience Inc1986-12-31Not applicableCanada
ColyteSodium sulfate decahydrate (22.72 g/4L) + Polyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L)Powder, for solutionNasogastricMEDA Pharmaceuticals2014-08-05Not applicableUs
Colyte with flavor packsSodium sulfate decahydrate (22.72 g/4L) + Polyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical1999-04-072016-08-31Us
Eau Purgative RigaSodium sulfate (1.056 g) + Magnesium sulfate (2.4 g)LiquidOralGlendale Agencies1978-12-311996-11-29Canada
Electropeg SolutionSodium sulfate (22.7 g) + Polyethylene glycol (238.8 g) + Potassium chloride (3 g) + Sodium bicarbonate (6.7 g) + Sodium chloride (5.8 g)PowderOralTechnilab Pharma Inc.1998-04-201999-09-27Canada
GaviLyte - C TMSodium sulfate (22.72 g/278.26g) + Polyethylene glycol (240 g/278.26g) + Potassium chloride (2.98 g/278.26g) + Sodium bicarbonate (6.72 g/278.26g) + Sodium chloride (5.84 g/278.26g)Powder, for solutionOralLupin Pharmaceuticals2009-01-06Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Sodium polysulthionate and folic acidSodium sulfate decahydrate (8 mg/1) + Folic acid (1 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralSolubiomix2016-08-242017-10-16Us
Sodium polysulthionate, 5-methyltetrahydrofolateSodium sulfate decahydrate (2 g/100g) + Levomefolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g)PowderOral; TopicalSolubiomix2015-07-212016-01-12Us
Sodium Polysulthionate, 5-mthfSodium sulfate decahydrate (8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralSolubiomix2016-01-092016-01-12Us
XizflusSodium sulfate decahydrate (8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralBasiem2016-01-092016-01-12Us
XizflusSodium sulfate decahydrate (2 g/100g) + 5-methyltetrahydrofolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g)PowderOral; TopicalBasiem2015-07-142016-01-12Us
Categories
UNII
36KCS0R750
CAS number
7757-82-6
Weight
Average: 142.042
Monoisotopic: 141.931268528
Chemical Formula
Na2O4S
InChI Key
PMZURENOXWZQFD-UHFFFAOYSA-L
InChI
InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
IUPAC Name
disodium sulfate
SMILES
[Na+].[Na+].[O-]S([O-])(=O)=O

Pharmacology

Indication

indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

Associated Therapies
Pharmacodynamics

Induces catharsis by the osmotic effects of the unabsorbed sulfate salts and polyethylene glycol (PEG) in the GI tract. Specifically, sulfate salts provide sulfate anions, which are poorly absorbed, and PEG, which is primarily unabsorbed, causes water to be retained in the GI tract resulting in watery diarrhea.

Mechanism of action

MoviPrep produces a watery stool leading to cleansing of the colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken with 1 liter of additional clear fluid, usually results in no net absorption or excretion of ions or water.

TargetActionsOrganism
ACarbonic anhydrase 2
inhibitor
Humans
ACarbonic anhydrase 1
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Absorption of sodium sulfate after ingestion in rats was investigated. 35)S-Radioactivity excreted in urine during 24 hr indicated almost complete absorption from GI tract. Determination in serum 2 hr after admin revealed 3-fold increase in sulfate concentration rapid and almost complete absorption of inorganic sulfate occurs after oral admin in rats.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Rectal effluent if unabsorbed sulfates ; urine (predominant route for absorbed sulfates )

Half life

Serum sulfate: 8.5 hours

Clearance
Not Available
Toxicity

Mouse LD50 (Oral): 5989mg/kg Mouse LDLo (Intravenous): 1220mg/kg Rabbit LD50 (Intravenous):1220mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium sulfate.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AclidiniumThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Aclidinium.
AcrivastineSodium sulfate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Morris ME, Levy G: Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate. Clin Pharmacol Ther. 1983 Apr;33(4):529-36. [PubMed:6831833]
  2. Cocchetto DM, Levy G: Absorption of orally administered sodium sulfate in humans. J Pharm Sci. 1981 Mar;70(3):331-3. [PubMed:7264905]
  3. Pubchem [Link]
  4. DRUGS.COM [Link]
  5. DAILYMED [Link]
  6. ChemIDplus [Link]
  7. inChem [Link]
  8. Wikipedia [Link]
External Links
KEGG Drug
D01732
KEGG Compound
C13199
PubChem Compound
24436
PubChem Substance
347827857
ChemSpider
22844
BindingDB
50101993
ChEBI
32149
ChEMBL
CHEMBL233406
Wikipedia
Sodium_sulfate
ATC Codes
A06AD13 — Sodium sulfateA12CA02 — Sodium sulfate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1Not Yet RecruitingTreatmentEffect of Drugs1
1Not Yet RecruitingTreatmentPharmacokinetics1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
2Active Not RecruitingTreatmentBowel Preparation Before Colonoscopy1
2CompletedDiagnosticMalignant Neoplasm of Colon1
2CompletedOtherBowel preparation therapy1
2CompletedOtherColon Prep for Colonoscopy1
2CompletedScreeningHealthy Volunteers1
2CompletedTreatmentColonoscopy1
2CompletedTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Disorders1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableSubjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedDiagnosticPatients Who Receive Colonoscopy1
3CompletedOtherBowel Cleansing Efficacy / Unrecognized Condition1
3CompletedScreeningCarcinoma, Colorectal / Colon Cleansing / Colorectal Cancers1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedSupportive CareColonic Diseases / Diabetes Mellitus (DM)1
3CompletedTreatmentBowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel1
3CompletedTreatmentColon Diseases / Colonoscopy Preparation1
3CompletedTreatmentColonoscopy3
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMalignant Neoplasm of Colon1
3RecruitingOtherDigestive System Diseases1
3RecruitingTreatmentBowel Preparation Before Colonoscopy1
3RecruitingTreatmentBowel preparation therapy1
3Unknown StatusDiagnosticColonoscopy1
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentBowel preparation therapy / Colonoscopy / Endoscopy1
4CompletedTreatmentColon Cleansing for Colonoscopy1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentGastrointestinal Diseases1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentSubjets Requiring a Colonoscopy1
4Enrolling by InvitationDiagnosticColonoscopy1
4RecruitingDiagnosticBowel Preparation Solutions1
4RecruitingDiagnosticColon Adenomas / Colon Lesion / Colon Polyps1
4RecruitingDiagnosticUlcerative Colitis1
4RecruitingHealth Services ResearchColorectal Cancers1
4Unknown StatusHealth Services ResearchColonoscopy1
Not AvailableCompletedNot AvailableEase of Bowel Preparation and Patient Tolerability / Efficacy of Bowel Preparation1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableHyponatremia1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedDiagnosticBowel preparation therapy1
Not AvailableCompletedDiagnosticDiabetes Mellitus (DM)1
Not AvailableCompletedHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionHemolytic-uremic Syndrome (HUS) / Hemorrhagic Colitis / Intestinal Infection Due to E. Coli / Intestinal Infectious Disease1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticColonic Adenomas1
Not AvailableWithdrawnScreeningColorectal Cancers1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1
Not AvailableWithdrawnTreatmentColonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionNasogastric
LiquidOral
Powder, for solutionNasogastric; Oral
KitOral
Tablet, effervescentOral
Powder, for solutionOral
SolutionOral
PowderOral
Solution, concentrateOral
CapsuleOral
PowderOral; Topical
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7169381No2007-01-302024-09-01Us
US7658914No2010-02-092024-09-01Us
US6946149No2005-09-202023-03-07Us
US9326969No2016-05-032033-09-10Us
US9592252No2017-03-142032-08-11Us
US9707297No2017-07-182033-09-10Us
US8999313No2015-04-072033-09-10Us
US10016504No2018-07-102033-09-10Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal sulfates
Direct Parent
Alkali metal sulfates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal sulfate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
inorganic sodium salt (CHEBI:32149)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. UniProt [Link]
  2. ChEMBL [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. UniProt [Link]
  2. ChEMBL [Link]
  3. KEGG [Link]

Drug created on November 30, 2015 12:10 / Updated on November 02, 2019 04:32